In an exclusive interview with NBC News Massoud Motamed, a former inspector with the U.S. FDA, says the regulatory agency struggles to police overseas drug manufacturers who may hide problems in their production lines. Case in point, he cites the valsartan recall and the fact that more than a year before the notices went out, he had tried to sound the alarm on what he flagged as potential systemic problems at two facilities in China and India that produce the active ingredients in generic valsartan and other blood pressure medications. However, the FDA ultimately overruled his recommendation. Learn More